US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.33

-1.0900-8.78%

Post-market: 11.400.0700+0.62%19:30 EDT

Volume:299.63K

Turnover:3.40M

Market Cap:3.84B

PE:-536.97

High:11.39

Open:11.34

Low:11.19

Close:12.42

52wk High:12.60

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:2.20

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0211

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.88

PE(LYR):-536.97

Loading ...

Overview Company News Filings

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix Tightens Capital Structure as Incentive Rights Lapse and Are Cancelled

Telix Seeks ASX Quotation for New Employee Share Plan Securities

UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Why Is Telix Pharmaceuticals Stock Gaining Tuesday?

Benzinga_recent_news

Telix Says Part 1 of Late-Stage Trial of Prostate Cancer Treatment Achieves Primary Objectives

MT Newswires Live

Telix Pharmaceuticals Expected to Present Data from First Part of Phase Three Study to Seek Investigational New Drug Amendment, Jefferies Says

MT Newswires Live

Telix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%

MT Newswires Live

ASX Preview: Australian Shares to Rise After Trump Remarks; Telix Pharmaceuticals Reports Positive Prostate Cancer Trial Results

MT Newswires Live

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Telix to Release Escrowed Shares Tied to Lightpoint Acquisition

Telix Pharmaceuticals (TLPPF) Receives a Buy from Canaccord Genuity

Telix Targets Prostate And Brain Cancer Growth With AI And Glioma Push

Simply Wall St.

Investor Education Webinar

Citi Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging

Telix Pharmaceuticals Says Second Part of Prostate Cancer Study Enrolls Patients in Australia, Canada, New Zealand

MT Newswires Live

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Strong Guidance And Gozellix Medicare Momentum

Simply Wall St.

Stock Track | Telix Pharmaceuticals Soars 9.57% Intraday on Strong 2026 Guidance and European Regulatory Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/TLX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":11.33,"timestamp":1787342400000,"preClose":12.42,"halted":0,"volume":299625,"hourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"delay":0,"changeRate":-0.08776167471819644,"floatShares":272000000,"shares":339000000,"eps":-0.0211,"marketStatus":"Market Closed","change":-1.09,"latestTime":"08-21 16:00:00 EDT","open":11.34,"high":11.39,"low":11.19,"amount":3395453.5710000005,"amplitude":0.016103,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":12.42,"preHourTrading":{"tag":"盘前","latestPrice":11.3,"preClose":12.42,"latestTime":"09:29 EDT","volume":9930,"amount":113052.21588,"timestamp":1787318999999,"change":-1.12,"changeRate":-0.090177,"amplitude":0.02818},"postHourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"volumeRatio":2.1988469508579978},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":2.1988469508579978,"shares":339000000,"dividePrice":0,"high":11.39,"amplitude":0.016103,"preClose":12.42,"low":11.19,"week52Low":6.28,"pbRate":"7.88","psRate":"4.31","week52High":12.5999,"institutionHeld":0,"latestPrice":11.33,"eps":-0.0211,"divideRate":0,"volume":299625,"delay":0,"ttmEps":-0.0211,"open":11.34,"prevYearClose":7.49,"prevWeekClose":11.82,"prevMonthClose":9.89,"prevQuarterClose":11.53,"fiveDayClose":11.82,"twentyDayClose":10.22,"sixtyDayClose":9.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-08-21","current":-536.966825,"percent":0.281179,"low":-584.49693,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"high":383.853933,"avg":21.978205,"sd":314.696392,"marketCap":3778875522.96},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96}],"updateTime":1787483231630},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618397415","title":"Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618397415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618397415?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:15","pubTimestamp":1773270920,"startTime":"0","endTime":"0","summary":"In a report released today, John Hester from Bell Potter maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$19.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618681971","title":"Telix Tightens Capital Structure as Incentive Rights Lapse and Are Cancelled","url":"https://stock-news.laohu8.com/highlight/detail?id=2618681971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618681971?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:11","pubTimestamp":1773267075,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has reported the cessation of several classes of equity-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-tightens-capital-structure-as-incentive-rights-lapse-and-are-cancelled?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-tightens-capital-structure-as-incentive-rights-lapse-and-are-cancelled?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618716359","title":"Telix Seeks ASX Quotation for New Employee Share Plan Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2618716359","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618716359?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:11","pubTimestamp":1773267064,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has applied to the ASX for quotation of 50,782 new fully...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-seeks-asx-quotation-for-new-employee-share-plan-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-seeks-asx-quotation-for-new-employee-share-plan-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618396777","title":"UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396777?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:05","pubTimestamp":1773183925,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$31.00. Dai covers the Healthcare sector, f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618193237","title":"Why Is Telix Pharmaceuticals Stock Gaining Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618193237","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618193237?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:01","pubTimestamp":1773140460,"startTime":"0","endTime":"0","summary":"Telix Pharma's ProstACT study achieves primary objectives, positioning TLX591-Tx as potential first-line treatment for prostate cancer.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/10/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/10/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51151940/why-is-telix-pharmaceuticals-stock-gaining-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51151940/why-is-telix-pharmaceuticals-stock-gaining-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SMA","BK4139","BK4217","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618982263","title":"Telix Says Part 1 of Late-Stage Trial of Prostate Cancer Treatment Achieves Primary Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2618982263","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618982263?lang=en_us&edition=fundamental","pubTime":"2026-03-10 15:52","pubTimestamp":1773129179,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said late Monday that part 1 of a phase 3 trial of TLX591-Tx in patients with metastatic castration resistant prostate cancer achieved its primary objectives.Results of the study showed an acceptable safety and tolerability profile with no new safety signals observed, the company said.Telix also said it has advanced the study into part 2.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","SSI","TLX","BK4139","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618988794","title":"Telix Pharmaceuticals Expected to Present Data from First Part of Phase Three Study to Seek Investigational New Drug Amendment, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2618988794","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618988794?lang=en_us&edition=fundamental","pubTime":"2026-03-10 12:38","pubTimestamp":1773117527,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  is expected to present data from the first part of its ProstACT Global phase three study to the US Food and Drug Administration  to seek an Investigational New Drug amendment to progress the second part in the US, which is expected to be granted, according to a Tuesday note by Jefferies.Telix said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel.Grade 3 and 4 thrombocytopenia across the three groups in the study was 45%, with rapid thrombocytopenia recovery in the docetaxel group by day 50.The investment firm retained its buy rating and its AU$23.40 per share price target.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618607397","title":"Telix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618607397","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618607397?lang=en_us&edition=fundamental","pubTime":"2026-03-10 11:06","pubTimestamp":1773112015,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel, according to a Tuesday Australian bourse filing.The tolerability profile was supported by dosimetry and low-grade non-hematologic events; the lesion dosimetry indicated no difference in absorbed dose profile across groups, and no adverse drug-drug interactions were observed in TLX591-Tx combinations.The patient population consisted of patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. ProstACT Global is a differentiated phase 3 trial comparing PSMA-targeted lutetium-177 rosopatamab tetraxetan therapy administered with standard-of-care compared with standard-of-care alone.Its shares ju","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK4139","BK7067","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618087686","title":"ASX Preview: Australian Shares to Rise After Trump Remarks; Telix Pharmaceuticals Reports Positive Prostate Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618087686","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618087686?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:11","pubTimestamp":1773097882,"startTime":"0","endTime":"0","summary":"Australian shares are poised to rise on Tuesday after US President Donald Trump's remarks suggesting the conflict with Iran may be nearing an end, easing market uncertainty.Overnight, the S&P 500, the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","FMG.AU","BK7129","BK7507","BK7067","TLX","XJO.AU","XKO.AU","TLX.AU","XAO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618366608","title":"ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2618366608","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618366608?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:34","pubTimestamp":1773095640,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx  – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, Salt Lake City, and ProstACT Global Principal Investigator and Steering Committee member, commented, \"These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic advers","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-study-part-1-achieves-primary-objectives-302708664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","TLX.AU","IND","ASX.AU","BK4526","BK4213","SOC","BK7067","BK4543","RLT.AU","BK7061","SOC.AU","BK7039","BK4139","IND.AU","ASX","BK4141","BK7142","TLX","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618691503","title":"Telix to Release Escrowed Shares Tied to Lightpoint Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2618691503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618691503?lang=en_us&edition=fundamental","pubTime":"2026-03-09 05:42","pubTimestamp":1773006157,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals will release 41,697 ordinary shares from voluntary escro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-to-release-escrowed-shares-tied-to-lightpoint-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-to-release-escrowed-shares-tied-to-lightpoint-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616305826","title":"Telix Pharmaceuticals (TLPPF) Receives a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2616305826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616305826?lang=en_us&edition=fundamental","pubTime":"2026-03-04 08:05","pubTimestamp":1772582730,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$28.50. Storey covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616315851","title":"Telix Targets Prostate And Brain Cancer Growth With AI And Glioma Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2616315851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616315851?lang=en_us&edition=fundamental","pubTime":"2026-03-03 12:46","pubTimestamp":1772513199,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has entered an AI research collaboration with University Hospital Essen focused on PSMA-PET imaging in prostate cancer.\nThe partnership will use Telix’s AI tools and the PROMISE-PET registry to build prognostic models for prostate cancer imaging.\nTelix has also submitted a European marketing authorization application for TLX101-Px, an advanced glioma imaging candidate.\nThe glioma submission aims to address the need for more consistent, high-quality brain...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-targets-prostate-and-brain-cancer-growth-with-ai-and-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-targets-prostate-and-brain-cancer-growth-with-ai-and-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4543","BK7067","TLX.AU","BK4587","BK4023","TLX","AIYY","BK4585","BK4551","BK4528","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2616723518","title":"Investor Education Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2616723518","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616723518?lang=en_us&edition=fundamental","pubTime":"2026-03-02 06:57","pubTimestamp":1772405820,"startTime":"0","endTime":"0","summary":"The Future of Prostate Imaging: What do physicians want?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/01/3246978/0/en/Investor-Education-Webinar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4141","BK4526","BK4139","ASX","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616687473","title":"Citi Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616687473","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616687473?lang=en_us&edition=fundamental","pubTime":"2026-03-02 06:37","pubTimestamp":1772404659,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Sutcliffe from Citi maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$32.00. Sutcliffe c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614580218","title":"Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2614580218","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614580218?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:00","pubTimestamp":1772193600,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246428/0/en/Telix-Joins-Forces-with-University-Hospital-Essen-on-PROMISE-PET-Optimizing-Patient-Management-through-AI-enabled-PSMA-PET-Imaging.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4526","BK4139","BK4543","ASX","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614886689","title":"Telix Pharmaceuticals Says Second Part of Prostate Cancer Study Enrolls Patients in Australia, Canada, New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886689","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886689?lang=en_us&edition=fundamental","pubTime":"2026-02-27 14:19","pubTimestamp":1772173141,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said part two of its ProstACT global study evaluating its radiopharmaceutical candidate, TLX591, for the potential treatment of patients with metastatic castration resi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","NZ20C.NZ","T10G.NZ","XKO.AU","BK4139","TLX","NZ50G.NZ","XAO.AU","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614000968","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Strong Guidance And Gozellix Medicare Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2614000968","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614000968?lang=en_us&edition=fundamental","pubTime":"2026-02-27 11:37","pubTimestamp":1772163447,"startTime":"0","endTime":"0","summary":"Why Telix’s latest guidance is attracting fresh attention\nTelix Pharmaceuticals (ASX:TLX) is back on many investors’ radar after the company issued 2026 revenue guidance of US$950 million to US$970 million and highlighted strong 2025 results supported by Gozellix uptake and Medicare reimbursement.\nSee our latest analysis for Telix Pharmaceuticals.\nThat guidance and the recent Gozellix and TLX101 Px updates have arrived after a volatile spell, with a 1 day share price return of 10.87% and a 1...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-stron","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-stron","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","TLX","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176967494","title":"Stock Track | Telix Pharmaceuticals Soars 9.57% Intraday on Strong 2026 Guidance and European Regulatory Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1176967494","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176967494?lang=en_us&edition=fundamental","pubTime":"2026-02-27 03:16","pubTimestamp":1772133400,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. (TLX) experienced a significant intraday surge of 9.57% on Thursday, reflecting strong investor sentiment toward the company's latest announcements.The substantial price...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":199,"code":"91000000","status":"200"}]}}